Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16363146 | 0.89 | MAPT (0.42) | MAPTSCN5ARECQLMEN1KMT2A | |
| SCHEMBL21719610 | 0.75 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL4785865 | 0.75 | MAPT (0.38) | MAPTSCN5ARECQLMEN1KMT2A | |
| SCHEMBL13092992 | 0.75 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL13902748 | 0.72 | HSD11B1 (0.33) | SCN5ATSHRHSD11B1 | |
| SCHEMBL10104242 | 0.72 | GAA (0.33) | MEN1KMT2A | |
| SCHEMBL13095083 | 0.72 | — | — | |
| SCHEMBL13814459 | 0.71 | MAPT (0.50) | MAPTRECQLMEN1KMT2ATSHR | |
| SCHEMBL21719415 | 0.70 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL21719587 | 0.70 | MEN1 (0.38) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| US-20220013735-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2022-01-13 | — | — | US | disclosed |
| US-8247401-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220013735-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OXA1L, ICOSLG, ODC1 | MAPT 1937/4885SCN5A 1976/4885RECQL 1811/4885 |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | MAPT 4011/4885SCN5A 377/4885RECQL 2398/4885 |
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | MAPT 651/4885SCN5A 378/4885RECQL 2736/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | MAPT 651/4885SCN5A 378/4885RECQL 2736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.